Stock Track | Artivion Plummets 35.54% Intraday After Lowered 2026 Guidance and Analyst Price Target Cuts

Stock Track

Yesterday

Artivion's stock plummeted 35.54% during intraday trading on Friday, extending significant losses from the previous session.

The sharp decline follows the company's recent first-quarter earnings report and a downward revision of its full-year 2026 financial outlook. Artivion lowered its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast, prompting multiple Wall Street analysts to slash their price targets on the stock.

Investor sentiment was further impacted by Artivion's announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash. The acquisition and more cautious financial forecast led to a wave of analyst downgrades, with firms including Canaccord Genuity, Stifel, Citizens, and Oppenheimer all reducing their price targets on the healthcare company's shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1178807149"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178807149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178807149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178807149","market":"sg","top_or_hot":-1,"title":"Stock Track | Artivion Plummets 35.54% Intraday After Lowered 2026 Guidance and Analyst Price Target Cuts","media":"Stock Track","content":"<p>Artivion's stock plummeted 35.54% during intraday trading on Friday, extending significant losses from the previous session.</p><p>The sharp decline follows the company's recent first-quarter earnings report and a downward revision of its full-year 2026 financial outlook. Artivion lowered its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast, prompting multiple Wall Street analysts to slash their price targets on the stock.</p><p>Investor sentiment was further impacted by Artivion's announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash. The acquisition and more cautious financial forecast led to a wave of analyst downgrades, with firms including Canaccord Genuity, Stifel, Citizens, and Oppenheimer all reducing their price targets on the healthcare company's shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Artivion Plummets 35.54% Intraday After Lowered 2026 Guidance and Analyst Price Target Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Artivion Plummets 35.54% Intraday After Lowered 2026 Guidance and Analyst Price Target Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Artivion's stock plummeted 35.54% during intraday trading on Friday, extending significant losses from the previous session.</p><p>The sharp decline follows the company's recent first-quarter earnings report and a downward revision of its full-year 2026 financial outlook. Artivion lowered its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast, prompting multiple Wall Street analysts to slash their price targets on the stock.</p><p>Investor sentiment was further impacted by Artivion's announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash. The acquisition and more cautious financial forecast led to a wave of analyst downgrades, with firms including Canaccord Genuity, Stifel, Citizens, and Oppenheimer all reducing their price targets on the healthcare company's shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AORT","symbol_name":"Artivion","start_time":0,"source_url":"","article_id":"1178807149","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178807149","pubTimestamp":1778248512,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Artivion's stock plummeted 35.54% during intraday trading on Friday, extending significant losses from the previous session.The sharp decline follows the company's recent first-quarter earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AORT":"Artivion"},"translate_title":"个股追踪|Artivion在下调2026年指引和分析师目标价后盘中暴跌35.54%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1},"content_text":"Artivion's stock plummeted 35.54% during intraday trading on Friday, extending significant losses from the previous session.The sharp decline follows the company's recent first-quarter earnings report and a downward revision of its full-year 2026 financial outlook. Artivion lowered its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast, prompting multiple Wall Street analysts to slash their price targets on the stock.Investor sentiment was further impacted by Artivion's announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash. The acquisition and more cautious financial forecast led to a wave of analyst downgrades, with firms including Canaccord Genuity, Stifel, Citizens, and Oppenheimer all reducing their price targets on the healthcare company's shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}